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Abstract 
The heart and the gut seem to be two organs that do not have much in common. However, 
there is an obvious and clinically relevant impact of gut functions on the absorption of drugs 
and oral therapies on one hand. On the other hand the gut determines the quantity of 
nutrient uptake and plays a central role in metabolic disease. Patients with inflammatory 
bowel diseases appear to have a higher risk for coronary heart disease despite a lower 
prevalence of “classical” risk factors indicating additional links between the gut and the 
heart. However, they certainly have a “leaky” intestinal barrier associated with increased 
permeability for bacterial wall products. An impaired intestinal barrier function will be 
followed by bacterial translocation and presence of bacterial products in the circulation 
which can contribute to atherosclerosis and chronic heart failure as recent data indicate. 
Impaired cardiac function in chronic heart failure vice versa impacts intestinal 
microcirculation leading to a barrier defect of the intestinal mucosa and increased bacterial 
translocation. These pathways and the most recent insights in the impact of the gut on acute 
and chronic heart disease will be discussed in this review.     
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The gut and its impact on heart diseases  
The gut cetainly is not the first organ we would think about when we consider the 
pathophysiology of heart diseases. However its basic functions, digestion and absorption 
obviously are clinically relevant for almost all oral drug treatments of diseases.  
The absorption of drugs from the small intestine is altered in its kinetics in patients with 
Crohn’s disease or celiac disease 1. Patients with undetected celiac disease or with 
inconsequent diet have a decreased expression of some cytochrome P450 (CYP) isoenzymes 
such as CYP3A 2. CYP3A is constitutively expressed in small intestinal villi and contributes to 
an important prehepatic metabolism of a number of drugs. Already in the intestine CYP3A 
mediates the oxidative biotransformation of various clinically important drugs 3. Macrolide 
antibiotics (which will be discussed in another role further below) are important inhibitors of 
CYP3A 3. Statins have been reported to increase CYP3A isoenzymes expression 4 and on the 
other hand are metabolized by them 4. CYP3A4 and CYP3A5 metabolize statins and thus 
have been demonstrated to influence the pharmacokinetics, efficacy and safety of statins 4 
indicating that small intestinal disease such as Crohn’s disease and celiac disease may well 
have a profound impact on the medical therapy of heart diseases.  
It is not surprising that diarrhea, associated with the mentioned diseases but also with other 
gut pathologies such as infectious enteritis, ulcerative colitis, radiation colitis alters the 
absorption of drugs 5, 6 which has to be kept in mind, when treating patients with heart 
diseases. 
 
 
 
Rogler and Rosano The heart and the gut 4 
 
Gut and heart disease: Is there a link? 
Several intestinal diseases have been reported to be associated with an increased risk for 
coronary heart disease. In a recent study from Finland coronary heart disease (CHD) 
occurred significantly more frequently in inflammatory bowel disease (IBD) patients as 
compared to an age and sex matched control group (p=0.004) 7. Patients with IBD, however, 
usually do not have the “classical” risk factors. In a respective analysis only hypertension was 
confirmed as risk factor 8. In addition Crohn’s disease patients seem to have lower levels of 
high density lipoprotein (HDL) 9. This could be due to the chronic inflammation as it was 
mainly associated with flares of the disease 9. As most patients with IBD are in remission the 
question arises whether there could be additional clinically relevant connections between 
the gut and the heart. A lower absorption of drugs during active flares of the disease as 
indicated above might certainly be relevant, however, the increased risk for coronary heart 
disease was also observed in IBD patients without cardiologic medication. 
 
The gut, the intestinal bacteria and general health/metabolic syndrome  
Recent years have brought interesting insights into the interaction of the gut microbes (the 
so-called “microbiome”) with the intestinal mucosa. Those interactions may impact the 
function other organs such as the lung, the heart or the lymphatic system. It is obvious that 
learning more about these interactions will become clinically relevant in the near future. 
Signals sent out from the intestinal microbiome, factors released by microbes and then 
absorbed, components of microbes (such as endotoxin or DNA) or factors induced in and 
secreted by intestinal epithelial cells or intestinal dendritic cells appear to have important 
physiological and pathophysiological functions. 
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It is estimated that there are 1000–1500 bacterial species that colonize the human gut, and 
that the gene content of microbes in the human gut may exceed that of the host by a factor 
of 100 or more 10, 11. Recent analyses of the human microbiome have revealed that even 
healthy individuals differ remarkably in their gut microbes 12. It is clear that diet, bacterial 
composition of the environment and host genetics play an important role for the individual 
composition of the microbiome 12.  
Many acute and chronic disorders affecting the heart, such as obesity 13-18 or metabolic 
syndrome 19 have been linked to inadequate, or disturbed postnatal microbiome acquisition 
or environmental microorganism exposure during early childhood 20. Obese patients seem to 
harbor different bacterial species as compared to the lean population, especially Firmicutes 
13-18. Further, chronic inflammatory diseases such as atopic dermatitis 21, asthma 22, allergy 23 
and inflammatory bowel disease 24-27 also have been linked with disturbances of the 
intestinal microbiome. 
The commensals are important components of the digestive system and provide a number 
of micronutrients and small molecules further shaping the metabolome of the gut 28 and the 
overall metabolism of the organism. The commensal flora takes part in orchestrating 
immune responses in physiological and pathophysiological situations 29.  
As mentioned obesity and metabolic syndrome, well known risk factors for hypertension or 
heart disease, have been linked to the presence of specific bacteria or families of bacteria in 
the intestinal microbiome 13-18, 30, 31. Especially the landmark studies by Turnbaugh and 
Gordon have raised important insights into the role of gut bacteria for the metabolic 
syndrome 14, 17, 18, 32, 33. Lean mice transplanted with the microbiome of obese mice showed a 
significant weight gain despite no change in food intake. Similar microbiome patterns as in 
obese mice were observed in obese patients or individuals with a metabolic syndrome. 
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Unfortunately the transplantation of the microbiome of lean mice into obese mice did not 
induce a weight loss in the latter. Therefore, these findings have no impact for clinical 
practice so far. However, the findings indicate that there are indeed patients that may have 
more weight gain and higher blood glucose levels with the same amount of daily caloric 
intake depending on the type of bacteria they host in their gut. This may at least change our 
attitude to patients with metabolic syndrome to some extent. 
 
The gut and atherosclerosis 
A recent study by Wang and colleagues using a metabolomics approach identified a novel 
pathway linking dietary lipid intake, gut microflora and atherosclerosis 34. The investigators 
identified the metabolism of phosphatidylcholine by the gut flora to be important for the 
development of cardiovascular disease 34. Three metabolites of phosphatidylcholine 
(choline, trimethylamine N-oxide (TMAO) and betaine) were shown to predict risk for 
cardiovascular disease in a large clinical cohort. This was not observed in germ-free animals 
confirming a crucial role for the gut flora in phosphatidylcholine metabolism. Additional 
prospective studies will be needed to evaluate whether these parameters are useful in 
clinical practice. 
The above results have raised a number of speculations that probiotic interventions may be 
beneficial and prevent the development of atherosclerosis and heart disease. Such 
conclusions should be handled with care. Health claims for food products are now more 
restricted and supervised by the European Food Safety Authority (EFSA).  
Several studies have shown an association between both viral and bacterial infections and 
degree of atherosclerosis. The mechanisms through which viral infections may favour the 
development of atherosclerosis are not obvious while there is plausibility for the influence of 
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intestinal bacterial infections and atherosclerosis 35. Bacterial lipopolysaccharides (LPS) may 
interact with LDL and influence lipoprotein metabolism thereby contributing to the 
development of atherosclerosis 36-40.  Furthermore LPS induces endothelial cell damage 41-43 
and stimulates the production and release of superoxide anion (O2-) 44, 45 and the oxidation 
of LDL 46. Oxidized LDL in turn favour the development of atherosclerosis and the release of 
cytokines, such as interleukin 1 (IL-1) and tumour necrosis factor alpha (TNF alpha) from 
macrophages stimulating their transformation into foam cells 47, 48.  
Whether the progression of atherosclerosis is supported or accelerated by bacterial infection 
or by LPS is still a matter of speculation.  While the results of antibiotic intervention studies 
have been somewhat discouraging, mechanistic evidence suggests a shift of focus from 
bacteria to endotoxins.  Patients with highest serum LPS levels have an increased incidence 
of carotid atherosclerosis 49. This might be clinically relevant in patients with an impairment 
of the intestinal barrier function such as IBD patients or patients with liver cirrhosis. Those 
patients frequently have largely increased serum LPS levels. Since the ability of endotoxin to 
promote atherosclerosis may depend on its ability to initiate an inflammatory response 
additional regulatory factors have been investigated. Polymorphisms of the Toll receptor 4 – 
which is the receptor for endotoxin of Gram negative bacteria - have been implicated in the 
development of coronary artery disease 50. The Toll receptor 4 is expressed amongst other 
tissues on cardiomyocytes and foam cells 47, 51-54. Kiechl et al have shown that the presence 
of a common polymorphism of TLR4 predicted low levels of circulating inflammatory 
molecules and conferred a reduced risk of atherosclerosis 50. Thus, some evidence supports 
a link between gut-originated endotoxins and progression of atherosclerosis, however, 
further studies are needed to confirm this link, to better understand the mechanisms and 
develop clinical consequences. 
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The gut and coronary artery disease 
The link between enteric bacterial translocation and coronary artery disease is more elusive. 
Lam and co-authors treated rats orally with the broad-spectrum antibiotic Vancomycin to 
reduce total microbiota numbers and change the composition of the gut microbiome in an 
ischemia/reperfusion model of myocardial infarction 55. Oral administrated Vancomycin is 
only absorbed to a very low amount thus excluding a direct effect on the myocard. The 
addition of the antibiotic to the drinking water was associated with a reduction of infarction 
size and cardioprotection already was achieved after two days of antibiotic treatment 55. The 
protection, however, was lost again after Vancomycin supplementation was stopped for 
more than three days. It remains unclear, whether the association between coronary heart 
disease and bacterial pathogens, such as Helicobacter pylori and Chlamydia pneumonia may 
play a role here 56-62. It is generally believed that a chronic infection with these bacteria and 
the subsequent immune responses are a pre-requisite for a slow development of 
atherosclerosis 63-65. Subsequently those mechanisms are not likely to play a role in an 
ischemia/reperfusion model of myocardial infarction. Nevertheless, a direct anti-
inflammatory effect of the drug in this artificial setting cannot be excluded. 
As a clinical attempt to improve the outcome of acute myocardial ischemia in patients the 
administration of various antibiotics was studies in well-designed randomized trials. In the 
STAMINA trial 325 patients with acute myocardial infarction or unstable angina (acute 
coronary syndromes) were randomized to receive either a 1-week course of placebo or two 
different classical Helicobacter eradication antibiotic therapies (either A: amoxicillin (500 mg 
twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily) or  B: 
azithromycin (500 mg once daily), metronidazole (400 mg twice daily) and omeprazole (20 
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mg twice daily)) 66. Patients were followed for 1 year; end points were cardiac death or 
readmission with acute coronary syndrome. The authors report 17 cardiac deaths and 71 
readmissions with acute coronary syndrome in their study group. No difference was 
observed between the two antibiotic treatments, however, at 12 weeks and during the one 
year follow up there was a 36% reduction in all end points in patients receiving antibiotics 
compared with placebo (P=0.02) 66.  
In the ROXIS study the effect of Roxithromycin on the outcome of 202 patients with unstable 
angina or non-Q-wave myocardial infarction was assessed in a double-blind, randomized, 
prospective, multicenter, parallel-group, placebo-controlled study 67. Patients either 
received the macrolide Roxithromycin 150 mg orally twice a day or placebo orally twice a 
day for 30 days 67. The primary clinical endpoints (cardiac ischemic death, myocardial 
infarction, and severe recurrent ischemia) were assessed at day 31 in 202 patients on an 
intention-to-treat basis and a statistically significant reduction in the primary composite 
triple endpoint rates was observed in the Roxithromycin group 67. As reported in the 
publication the rates of severe recurrent ischemia, myocardial infarction, and ischemic death 
were 5.4%, 2.2%, and 2.2% in the placebo group and 1.1%, 0%, and 0%, in the Roxithromycin 
group 67. 
In contrast to the two described studies in the WIZARD trial no positive effect was reported- 
7747 adults with previous myocardial infarction that had occurred at least 6 weeks 
previously were randomized to placebo treatment or azithromycin (600 mg/d for 3 days 
during week 1, then 600 mg/week during weeks 2-12; n = 3879 68. After a median of 14 
months of follow-up, no significant risk reduction in the likelihood of occurrence of death, 
nonfatal re-infarction, coronary revascularization, or hospitalization for angina was found 
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comparing azithromycin with placebo (RRR: 7% [95% confidence interval: -5% to 17%], p = 
0.23) 68.  
For the interpretation of the results it appears to be important that in the large WIZARD 
study, patients were included with an AMI at least 6 months previously (median 2.6 years), 
thus lacking those cases with early cardiac events after AMI. This is in contrast with 
STAMINA and ROXIS studies which evaluated patients with ACS treated with antibiotics 
shortly after the initial event. 
It has been discussed that the positive effects of the clinical interventions may be attributed 
to the anti-Chlamydia activity of the antibiotics. However, as the impact of Chlamydia on 
atherosclerosis has been suggested to be mediated by a chronic inflammatory response the 
positive effect to the antibiotic treatment in acute myocardial infarction especially with 
respect to short-term (and not long-term) outcome is surprising. A direct anti-inflammatory 
effect of the antibiotics also might be relevant. Further studies are needed to finally answer 
these questions as a RRR between 37 and 80% would be clinically very important. 
 
The gut and heart failure 
An involvement of the gut in the progression and clinical evolution of heart failure has been 
discussed for years. Although the pathogenetic role of the gut microbiome and function 
have only recently started to be investigated in more detail in patients with chronic heart 
failure (CHF), data are accumulating to suggest that the gut plays an important 
pathophysiological role in both chronic inflammation and malnutrition in CHF.  
In patients with CHF, disturbed intestinal microcirculation and barrier function may trigger 
cytokine production that in turn contributes to impaired cardiac function 69. On the other 
hand, the circulatory adaptations that occur in patients with CHF as consequence of 
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myocardial dysfunction may favour microcirculatory injuries leading to a disruption in the 
intestinal barrier, thereby amplifying inflammation 69-71.  
Patients with CHF have morphological and functional alterations of the gut 69-71. In these 
patients all parts of the large bowel display a thickened wall as compared with control 
subjects of similar age 70. This is associated with a functionally altered gut mucosa with 
increased permeability for lactulose/mannitol and sucralose in both the small and large 
intestine as well as with a reduced passive carrier-mediated transport for D-xylose. 
Furthermore, in patients with CHF the concentration of bacteria in the sigmoidal mucosal 
biofilm and the extent of their adherence are higher than in control subjects 72.  
The translocation of bacteria across the intestinal barrier and the systemic presence of 
endotoxin such as lipopolysaccharide (LPS) or other bacterial wall compounds such as 
peptidoglycans (e.g. muramyl dipeptide) also may play a pathophysiological role in CHF 73. 
The hypothesis is supported by increased levels of soluble CD14 in patients with CHF 74. 
CD14 is a part of the LPS receptor and soluble CD14 (a form of CD14 that is shed from the 
cell membrane) is believed to have important regulatory functions in the sensing of LPS. As 
mentioned above, another component of the LPS receptor the Toll-Like receptor 4 (TLR-4) is 
expressed on cardiomyocytes 75. Binding of endotoxin to TLR-4 on cardiomyocytes is 
associated with impaired function 76, decreased contractility 52-54, induction of an 
inflammatory response 52, 54 and structural tissue damage.  
It is well known that CHF is a state of chronic inflammation with elevated circulating levels of 
pro-inflammatory cytokines, such as tumor necrosis factor (TNFα). In patients with CHF, 
increased circulating levels of pro-inflammatory cytokines have been shown to be closely 
related to predict poor short- and long-term survival 77, 78. Circulating cytokines have 
cardiosuppressor effects via different pathways that include alterations in myocardial 
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intracellular calcium homeostasis, reduction in mitochondrial activity, alterations in matrix 
metalloproteinase expression, cardiomyocyte hypertrophy and apoptosis 79-83.  
Although the origin of inflammation in patients with CHF with elevated concentrations of 
pro-inflammatory cytokines is still a matter of debate it has been shown that very small, 
albeit pathophysiological relevant amounts of LPS may induce TNFα release 84, 85. 
Furthermore, growing evidence suggest that increased amounts of LPS enter the systemic 
circulation because of an altered intestinal microcirculation in CHF with LPS levels being 35% 
higher in the hepatic venous blood than in the left ventricle 86. An important point in gut-
derived inflammation in patients with CHF is the altered gut circulation as a consequence of 
reduced cardiac output and venous congestion. 
In patients with CHF increased sympathetic tone and peripheral vasoconstriction contribute 
to a redistribution of blood flow away from the splanchnic circulation. The reduced intestinal 
perfusion may lead to an increase in intramucosal carbon dioxide pressure.  Intramucosal 
acidosis may occur in nearly 50% of patients with circulatory failure suggesting the presence 
of inadequate oxygen supply and intestinal ischemia 87, 88. The altered mucosal perfusion 
increases intestinal mucosal permeability with disruption of the epithelial barrier function 
that favour the bacterial colonization and the penetration of LPS. Besides its effect on the 
release of cytokines that further aggravates CHF, LPS is able to trigger catecholamine release 
by granulocytes and phagocytes 89. (This increased release of catecholamines exerts 
additional unfavorable effects on gut perfusion and further increase the already hyperactive 
sympathetic tone. 
Another mechanism through which CHF may favour bacterial translocation is related to 
intestinal mucosa congestion as a consequence of raised right atrial pressure.  As CHF is 
associated with mucosal edema in the intestine which will impair the intestinal barrier 
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function this again may be followed by increased bacterial translocation (across the impaired 
barrier), increased amounts of endotoxin in the circulation 90 and aggravated heart disease – 
a typical vicious circle. Niebauer and colleagues found that intensified diuretic treatment 
normalized circulating endotoxin concentrations in patients with acute exacerbation of 
chronic heart disease 90.  
A number of alterations in gastrointestinal function have been described in patients with 
chronic heart failure [Table 1]. It remains a matter of discussion whether these alterations 
are primary to the heart disease or caused by it. 
 
In summary recent data on potential interaction between the gut and the heart are 
intriguing. However, the evidence we have so far is preliminary. In large cohort studies it 
needs to be evaluated whether indeed increased levels of bacterial products can be found in 
patients with atherosclerosis or chronic heart failure. The interesting and innovative field of 
heart-gut interaction still waits for more cardiologists and gastroenterologists to collaborate 
on these important topics. 
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Tables 
 
Table 1: Alterations of gastrointestinal function in patients with CHF (according to 70) 
 
• Increased small intestinal and large intestinal paracellular permeability in stable 
compensated CHF patients  
• Diminished carrier-mediated transport for D-xylose  
• Excessive enteric protein loss in infants with severe congenital heart disease 
• Decreased absorption of fat and protein  
•  Thickened bowel wall of the terminal ileum and the colon 
•  Elevated collagen content in small intestinal biopsies  
• Increased distance between the capillary wall and the basal membrane of the 
enterocyte  
• Increased bacterial biofilm on sigmoid biopsies  
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Figures  
Figure 1: Potential pathways of gut involvement in the pathogenesis of atherosclerosis and 
coronary heart disease.  
The intestinal microbiota has a profound influence on mucosa barrier functions and on the 
nutritional/metabolic status of its “host”. Certain bacterial families such as “Firmicutes” 
contribute to a higher uptake for example of short chain fatty acids. In addition a leaky 
barrier or impaired intestinal epithelial barrier function allows bacterial products such as 
lipopolysaccharide, bacterial DNA (CpG motifs) or peptidoglycans to enter the circulation. 
Furthermore, the microbiota directly can influence the cytokine production of epithelial cells 
and innate immune cells. Those mediators also enter the circulation. LPS itself but also the 
metabolic situation can induce the production of oxidized LDL. These mediators are 
recognized by specific receptors (such as Toll-like receptors for bacterial wall products, 
cytokines receptors or scavenger receptors) on (or in) endothelial cells, macrophages or 
smooth muscle cells (SMCs) of the arterial wall. They are able to induce endothelial damage, 
foam cell formation and SMC proliferations which are features of atherosclerosis and 
coronary heart disease.  
 
Figure 2: The heart and the gut in the pathophysiology of chronic heart failure.  
Chronic heart failure will cause a reduction in cardiac output which in turn will cause central 
and peripheral hypoxia. Among the organs that are affected by peripheral hypoxia is the 
small and large intestine. Hypoxia will cause an increase in inflammatory cytokine 
production, sympathetic activity and production of other mediators (such as leukotrienes, 
prostaglandins and others that are not depicted in this graph). These mediators and the 
sympathetic activity may cause a malfunction of the gut. A further contributor will be a 
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venous stasis increasing mucosal hypoxia. The mentioned factors have been shown to impair 
epithelial barrier function leading to a penetration of bacterial products across the intestinal 
barrier. Preliminary data indicate that the presence of those products in the circulation 
further aggravate chronic heart failure. Further studies with modern technologies such as 
mass spectroscopy and pyro sequencing of bacterial DNA will be necessary to confirm this. 
On the other hand a dysfunction of the intestinal barrier will also cause impaired absorption 
negatively influencing the nutritional status of patients with end stage heart disease.  
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